Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Polycythemia vera.

Nathanial Berlin1, Nathanial I Berlin

  • 1Department of Medicine, Northwestern University, Chicago, IL, USA. nberlin@pol.net

Hematology/Oncology Clinics of North America
|October 17, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

For polycythemia vera, phosphorus-32 (32P) is recommended as a primary treatment due to its efficacy and manageable side effects, offering a better alternative to phlebotomy alone. This approach contrasts with concerns about chemotherapy

Area of Science:

  • Hematology
  • Oncology

Background:

  • Polycythemia vera diagnosis is straightforward, but therapeutic consensus remains elusive.
  • Phlebotomy alone leads to high rates of thrombotic events, rendering it unsustainable.
  • Pipobroman is no longer available, limiting treatment options.

Purpose of the Study:

  • To evaluate the optimal therapeutic strategy for polycythemia vera.
  • To compare the efficacy and safety of different treatment regimens.

Main Methods:

  • The study reviews existing data and expert opinions on polycythemia vera treatments.
  • Comparative analysis of treatment outcomes, including life expectancy, toxicity, and remission duration.

Main Results:

  • Phosphorus-32 (32P) therapy is proposed as the treatment of choice, offering long remissions (average 3.1 years, median 2 years) with acceptable toxicity.

Related Experiment Videos

  • Acute leukemia incidence with 32P is comparable to other regimens, excluding phlebotomy alone.
  • Phlebotomy alone is associated with an unacceptably high incidence of early thrombotic events.

    • Conclusions:

    • Phosphorus-32 (32P) should be considered the preferred treatment for polycythemia vera, except in pregnant women.
    • The efficacy, safety profile, and remission duration support the use of 32P over other methods.
    • Concerns about chemotherapy's tolerability are contrasted with the benefits of 32P therapy.